CSPC Pharmaceutical (HKG:1093) initiated two clinical trials at their first centers in China, according to two Hong Kong bourse filings on Thursday.

The pharma company began a phase II study of Sirolimus for Injection to treat patients with progressive/symptomatic epithelioid haemangioendothelioma.

A phase III clinical trial of SYS6043 versus chemotherapy for the treatment of participants with platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer was also initiated.